Literature DB >> 19925945

Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines.

Richard Franka1, Xianfu Wu, Felix R Jackson, Andres Velasco-Villa, Dustyn P Palmer, Heather Henderson, Wajid Hayat, Douglas B Green, Jesse D Blanton, Lauren Greenberg, Charles E Rupprecht.   

Abstract

Despite progress in vaccine development in the past century the mechanisms behind immune responses elicited by rabies biologics or via natural infection remain largely unknown. In this study, we compared protection elicited by standard, early, or delayed prophylaxis with a reduced number of vaccine doses using inactivated and live-attenuated vaccines. Two-month-old Syrian hamsters, 4-week-old ICR mice or adult rhesus macaques were inoculated with canine rabies virus variants. Thereafter, prophylaxis was initiated 6h, 1, 2, 3, 4, 5, 6 or 7 days post-exposure (p.e.). One or several doses of inactivated (HDCV), or reverse genetically attenuated (live), or gamma-irradiated (inactivated)-ERAG333 vaccines were administered intramuscularly. The dynamics of virus spread were measured over time in the rodent models. Rabies virus reached the spinal cord at day 4 and brain at day 6 p.e. All hamsters succumbed in groups in which live ERAG333 was delayed until days 5 and 6 p.e. However, 78%, 44%, 56% and 22% of hamsters survived when one dose of live ERAG333 was administered 6h, 1, 2, 3, and 4 days p.e., respectively. Similarly, 67% survived when inactivated ERAG333 was administered at 24h p.e. All hamsters succumbed when standard prophylaxis (the Essen regimen) was delayed until days 3-6, but 67% and 33% of hamsters survived when PEP began 1 or 2 days p.e., respectively. Macaques were protected by one dose of attenuated ERAG333 at 24h p.e. The highly attenuated (live) and inactivated ERAG333 vaccines elicited potent protective immune responses, even when prophylaxis initiation was delayed. When 2-5 doses of commercial vaccine and HRIG were administered according to the Essen scheme, 89-100% of the animals survived. Reduced vaccine schedules provided efficacious intervention, regardless of the total number of vaccine doses administered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925945     DOI: 10.1016/j.vaccine.2009.09.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Assessment of the immunogenicity of rabies vaccine preserved by vaporization and delivered to the duodenal mucosa of gray foxes (Urocyon cinereoargenteus).

Authors:  Todd G Smith; Xianfu Wu; James A Ellison; Ashutosh Wadhwa; Richard Franka; Gregory L Langham; Brianna L Skinner; Cathleen A Hanlon; Victor L Bronshtein
Journal:  Am J Vet Res       Date:  2017-06       Impact factor: 1.156

2.  Pre- and post-exposure safety and efficacy of attenuated rabies virus vaccines are enhanced by their expression of IFNγ.

Authors:  Darryll A Barkhouse; Milosz Faber; D Craig Hooper
Journal:  Virology       Date:  2014-11-19       Impact factor: 3.616

3.  Evaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countries.

Authors:  Katie Hampson; Sarah Cleaveland; Deborah Briggs
Journal:  PLoS Negl Trop Dis       Date:  2011-03-08

4.  Safety and immunogenicity of recombinant rabies virus (ERAGS) in mice and raccoon dogs.

Authors:  Dong-Kun Yang; Ha-Hyun Kim; Sung-Suk Choi; Jong-Tack Kim; Kang-Bok Lee; Seong Heon Lee; In-Soo Cho
Journal:  Clin Exp Vaccine Res       Date:  2016-07-29

5.  Novel Approaches to the Prevention and Treatment of Rabies.

Authors:  C W Gnanadurai; C T Huang; D Kumar; Zhen F Fu
Journal:  Int J Virol Stud Res       Date:  2015-04-07

6.  Epidemiology of Animal Bites and Factors Associated With Delays in Initiating Post-exposure Prophylaxis for Rabies Prevention Among Animal Bite Cases: A Population-based Study.

Authors:  Firooz Esmaeilzadeh; Abdolhalim Rajabi; Sajad Vahedi; Mohammad Shamsadiny; Mousa Ghelichi Ghojogh; Nahid Hatam
Journal:  J Prev Med Public Health       Date:  2017

7.  Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system.

Authors:  Jianhui Nie; Xiaohong Wu; Jian Ma; Shouchun Cao; Weijin Huang; Qiang Liu; Xuguang Li; Yuhua Li; Youchun Wang
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

8.  A single immunization with recombinant rabies virus (ERAG3G) confers complete protection against rabies in mice.

Authors:  Dong-Kun Yang; Keisuke Nakagawa; Naoto Ito; Ha-Hyun Kim; Bang-Hun Hyun; Jin-Ju Nah; Makoto Sugiyama; Jae-Young Song
Journal:  Clin Exp Vaccine Res       Date:  2014-06-20

9.  Oral immunization of mice with recombinant rabies vaccine strain (ERAG3G) induces complete protection.

Authors:  Dong-Kun Yang; Ha-Hyun Kim; Sung-Suk Choi; Jong-Taek Kim; Woong-Ho Jeong; Jae-Young Song
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

10.  Feasibility of sustainable provision of intradermal post exposure prophylaxis against rabies at primary care level--evidence from rural Haryana.

Authors:  Harshal Salve; Sanjeev Kumar; Rizwan Sa; Sanjay K Rai; Shashi Kant; Chandrakant S Pandav
Journal:  BMC Health Serv Res       Date:  2014-06-25       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.